

US Family Health Plan

Prior Authorization Request Form for elexacaftor - tezacaftor - ivacaftor (**Trikafta**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call **1-877-880-7007**

Step 1 Please complete patient and physician information (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

Step 2 Please complete the clinical assessment:

1. Is the requested medication being prescribed by or in consultation with a pulmonologist?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No STOP Coverage not approved
2. Is Trikafta being prescribed for the treatment of cystic fibrosis (CF)?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No STOP Coverage not approved
3. Is this drug being requested for an FDA approved age?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No STOP Coverage not approved
4. Does the patient have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by an FDA-approved CF mutation test?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Proceed to question 5
5. Does the patient have a mutation in the CFTR gene that is responsive based on in vitro data?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No STOP Coverage not approved
6. Is the genotype known or unknown?	<input type="checkbox"/> Known - Proceed to question 8 <input type="checkbox"/> Unknown - Proceed to question 7	
7. Has an FDA-approved test been used to detect the presence of at least one F508del mutation or a mutation that is responsive based on in vitro data?	<input type="checkbox"/> Yes Proceed to question 8	<input type="checkbox"/> No STOP Coverage not approved

8. Is this agent being used in combination therapy with Symdeko, Orkambi or Kalydeco?

Yes

No

STOP

Sign and date below

Coverage not approved

Step 3 I certify the above is true to the best of my knowledge. Please sign and date:

Prescriber Signature

Date

[09 June 2021]